Innocan Pharma Corporation (TSE:INNO) has released an update.
Innocan Pharma Corporation has taken its first stride towards FDA approval by submitting a Pre-IND Meeting Request Letter for its LPT-CBD injectable therapy for chronic pain, potentially offering a non-opioid alternative in a market projected to surpass $100 billion by 2032. The company’s LPT technology promises a monthly subcutaneous injection to manage pain, positioning it as a significant competitor to opioid treatments. This move aligns with Innocan’s commitment to advancing cannabinoid science for improving patient care and capitalizes on extensive pre-clinical research demonstrating the therapy’s effectiveness.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
